KOL Event tonight 10 Sept (by webcast), page-4

did anyone else listen to the presentation. I thought that it was interesting that they mentioned their agitation patent extends beyond their current trial and covers Autism Spectrum Disorder.

I think ASD will probably be another Phase 2 trial. My guess is the trial will be announced before the current Agitation trial results are in.

Would be interested in other people opinions.

I know everyone in small cap biotech thinks theirs is going to be bought out but I think that is probably on the cards now. In the presentation they reiterated that they don't really have the capacity to do a whole hog Phase 3 also I think the cancer assets have been deliberately taken off the table & the paid broker reports they are putting out all mention that it makes sense from an MSD POV.

Sounds like everyone is awaiting the ptsd results but the objective is to prove up 210 capabilities for sale.

Either way it seems unlikely that MSD would make an offer in the last 3 months of the calendar year.

all of this is only my opinion (baseless)